tiprankstipranks
Trending News
More News >
TG Therapeutics (TGTX)
NASDAQ:TGTX
Advertisement

TG Therapeutics (TGTX) AI Stock Analysis

Compare
2,048 Followers

Top Page

TGTX

TG Therapeutics

(NASDAQ:TGTX)

Rating:68Neutral
Price Target:
$40.00
▲(9.50%Upside)
TG Therapeutics demonstrates strong financial recovery and promising growth potential, as highlighted in the earnings call with increased sales and revenue guidance. However, the high P/E ratio and ongoing cash flow challenges present valuation concerns and liquidity risks.
Positive Factors
Commercial Performance
Record patient enrollments were observed despite headwinds and the recent product launch of a competitor, indicating minimal-to-no competitive impact.
Market Expansion
Briumvi is now commercially available in additional countries in the EU, UK, and Switzerland, which could translate into incrementally larger royalty revenue in the quarters ahead.
Revenue Growth
The company's revenue growth justifies additional pipeline investments.
Negative Factors
Competition
Ocrevus Zunovo still remains bigger risk to Briumvi growth.
Development Challenges
TG’s subq option remains behind in development, though less frequent dosing may be beneficial.
Market Perception
Analyst reiterates Underperform and $11 price objective on, in their view, an overvalued long-term market opportunity for Briumvi with key challenges to competitive pillars ahead.

TG Therapeutics (TGTX) vs. SPDR S&P 500 ETF (SPY)

TG Therapeutics Business Overview & Revenue Model

Company DescriptionTG Therapeutics (TGTX) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, NY, and operates within the healthcare sector, primarily targeting hematologic cancers and other B-cell related disorders. TG Therapeutics' core products include therapies aimed at transforming the treatment landscape for patients with these conditions.
How the Company Makes MoneyTG Therapeutics generates revenue through the sales of its pharmaceutical products, primarily focusing on innovative treatments for B-cell malignancies and autoimmune diseases. The company's revenue model is centered around the commercialization of its core products, which are developed through extensive research and clinical trials. Key revenue streams include product sales upon obtaining regulatory approval and entering the market. Additionally, TG Therapeutics may engage in strategic partnerships or collaborations with other pharmaceutical companies to enhance the development and distribution of its products, thereby contributing to its earnings. These partnerships may also involve licensing agreements, milestone payments, and royalties, which can provide additional financial support and revenue opportunities.

TG Therapeutics Earnings Call Summary

Earnings Call Date:May 05, 2025
(Q1-2025)
|
% Change Since: -15.91%|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant growth in BRIUMVI sales, increased revenue guidance, and advancements in the pipeline, suggesting strong commercial and financial performance. While there were some concerns about manufacturing expenses and potential tariffs, these were not expected to significantly impact overall performance.
Q1-2025 Updates
Positive Updates
BRIUMVI US Net Sales Growth
BRIUMVI US net sales reached nearly $120 million in the first quarter, exceeding expectations and marking a 137% year-over-year growth and 16% sequential quarter-over-quarter growth.
Raising Full-Year Revenue Guidance
Based on strong performance, TG Therapeutics raised their full-year 2025 US net revenue guidance for BRIUMVI to $560 million from a previous $525 million.
Pipeline and Innovation Strategy
TG Therapeutics is advancing a self-administered subcutaneous version of BRIUMVI and has initiated efforts in Myasthenia Gravis and azer-cel, a CD19 CAR-T cell therapy for progressive forms of MS.
Commercial Strategy Execution
The company reported strong commercial execution, with high repeat prescriptions and increasing prescriber confidence, leading to a robust start in 2025.
Financial Stability
TG Therapeutics ended the quarter with $276 million in cash, cash equivalents, and investment securities, indicating a strong financial position.
Negative Updates
Subcutaneous BRIUMVI Manufacturing Expenses
An increase in operating expenses was noted, primarily driven by $20 million in manufacturing investments for subcutaneous BRIUMVI.
Potential Tariff Concerns
There are ongoing discussions regarding potential tariffs as BRIUMVI is manufactured in South Korea, though the company does not expect a material impact on financial performance.
Company Guidance
During TG Therapeutics' first quarter 2025 conference call, the company reported strong financial performance, with BRIUMVI US net sales reaching approximately $119.7 million, reflecting a 137% year-over-year growth and 16% sequential quarter-over-quarter growth. This performance led to an increase in full-year 2025 US net revenue guidance from $525 million to $560 million. The company highlighted robust patient demand, with the highest months of new patient enrollment since launch, and a growing number of repeat prescriptions. The operating expenses for the quarter, excluding non-cash items, were about $82 million, tracking slightly ahead of the annual guidance of $300 million primarily due to manufacturing investments. The company reported a GAAP net income of approximately $5 million for the quarter, supported by a strong cash position of $276 million. Key strategic initiatives discussed included a direct-to-patient television campaign and ongoing development of a subcutaneous formulation of BRIUMVI, with plans to launch a pivotal trial this year.

TG Therapeutics Financial Statement Overview

Summary
TG Therapeutics shows a strong recovery trajectory with significant revenue and profit growth, alongside improved balance sheet metrics. However, the continued negative operating cash flow and historical financial instability present areas of concern.
Income Statement
75
Positive
TG Therapeutics has demonstrated strong revenue growth with a significant increase from $278,500 in 2022 to $386.4 million in TTM (Trailing-Twelve-Months). The gross profit margin improved to 87.4% in TTM, and net profit margin also rose to 10.1%, signaling enhanced operational efficiency. However, the past losses in earlier years indicate historical instability.
Balance Sheet
68
Positive
The company has managed to improve its financial health with positive stockholders' equity of $237.3 million in TTM. The debt-to-equity ratio is low at 0.038, indicating low leverage. However, the equity ratio of 36.1% suggests moderate reliance on liabilities, and past negative equity highlights previous financial distress.
Cash Flow
60
Neutral
The operating cash flow remains negative at -$61 million in TTM, though free cash flow has shown improvement. The company's ability to convert net income into cash flow is limited, posing a risk to liquidity despite substantial financing activities that sustain operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue329.00M233.66M2.79M6.69M152.00K
Gross Profit290.52M219.11M2.52M5.90M-222.00K
EBITDA49.90M26.10M-187.63M-341.97M-272.68M
Net Income23.38M12.67M-203.83M-355.55M-285.88M
Balance Sheet
Total Assets577.69M329.59M193.57M379.63M625.64M
Cash, Cash Equivalents and Short-Term Investments311.00M217.51M174.08M350.30M605.43M
Total Debt254.38M110.80M83.06M79.05M41.98M
Total Liabilities355.33M169.09M134.99M142.48M106.29M
Stockholders Equity222.36M160.50M-1.53B-1.33B519.35M
Cash Flow
Free Cash Flow-40.56M-31.41M-176.18M-296.04M-214.86M
Operating Cash Flow-40.52M-31.41M-176.17M-295.63M-214.51M
Investing Cash Flow-1.04M-50.65M-20.01M-332.00K-24.51M
Financing Cash Flow128.53M72.70M-391.00K41.42M679.83M

TG Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price36.53
Price Trends
50DMA
36.54
Negative
100DMA
37.67
Negative
200DMA
33.65
Positive
Market Momentum
MACD
0.20
Positive
RSI
46.22
Neutral
STOCH
22.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Negative. The current price of 36.53 is below the 20-day moving average (MA) of 37.25, below the 50-day MA of 36.54, and above the 200-day MA of 33.65, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 46.22 is Neutral, neither overbought nor oversold. The STOCH value of 22.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TGTX.

TG Therapeutics Risk Analysis

TG Therapeutics disclosed 74 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

TG Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$7.14B15.9112.25%5.76%49.58%
68
Neutral
$5.97B154.1019.70%33.54%-6.13%
62
Neutral
$5.77B-418.97%48.88%39.30%
58
Neutral
$6.75B-118.53%-7.65%-11.81%
54
Neutral
$5.24B-282.16%72.16%9.65%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
43
Neutral
$5.78B-35.69%-81.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TGTX
TG Therapeutics
36.53
15.97
77.68%
IONS
Ionis Pharmaceuticals
42.15
-9.30
-18.08%
JAZZ
Jazz Pharmaceuticals
118.01
6.44
5.77%
AXSM
Axsome Therapeutics
104.97
18.44
21.31%
RYTM
Rhythm Pharmaceuticals
87.27
38.22
77.92%
NUVL
Nuvalent
82.08
0.47
0.58%

TG Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
TG Therapeutics Approves Key Proposals at Annual Meeting
Neutral
Jun 13, 2025

On June 12, 2025, TG Therapeutics, Inc. held its Annual Meeting where stockholders representing 74.58% of the outstanding shares were present. All proposals, including the election of six directors, ratification of KPMG LLP as the independent auditor, approval of executive compensation, and amendment to the 2022 Incentive Plan, were approved, potentially impacting the company’s governance and financial strategies.

The most recent analyst rating on (TGTX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on TG Therapeutics stock, see the TGTX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 25, 2025